Abstract
Vascular Parkisonism (VP) can result from infarction or haemorrhage in the nigrostriatal pathway or from small vessel disease in the white matter.
Although it represents 2.5-5% of all Parkinsonism cases, VP is frequently misdiagnosed due to its resemblance to other disorders, the lack of definitive biomarkers, and the underestimation of vascular risk factors. A delay in diagnosis can result in inappropriate treatment, delayed management, increased disability, and a worse prognosis.
This article aims to delineate the essential clinical and diagnostic characteristics of VP to aid in its early identification and timely treatment in clinical practice.
Introduction
Parkinsonism is a clinical syndrome characterised by resting tremor, bradykinesia and cog-wheel rigidity [1]. It can have various causes, one of which is cerebrovascular disease, leading to vascular parkinsonism (VP) [2]. VP can result from infarction or haemorrhage in the nigrostriatal pathway, often causing hemiparkinsonism, or from small vessel disease in the white matter, leading to bilateral symptoms in the lower extremities known as ‘lower body parkinsonism’. The latter presents as a slow gait with short steps, progressing to wheelchair dependence. Patients may also experience urinary incontinence, abnormal pyramidal reflex responses and cognitive decline, with minimal Parkinsonian features and pyramidal signs in the upper body [3].
Despite accounting for 2.5-5% of all cases of Parkinsonism, VP is often misdiagnosed due to its similarities with other conditions, the absence of definitive biomarkers and underestimation of vascular risk factors [4]. Delay in diagnosis can lead to inappropriate treatment, delayed management, increased disability, and poorer prognosis. The purpose of this article is to outline the key clinical and diagnostic features of VP to facilitate its early recognition and prompt treatment in clinical practice.
Clinical features
Vascular parkinsonism typically presents with a predominant gait disorder, often referred to as lower body parkinsonism. The onset and evolution of symptoms are critical to establishing the diagnosis and should be carefully explored. In many cases, symptoms develop insidiously, with a gradual decline in gait speed, shortened step length, and early postural instability [5,6]. Less commonly, onset may be acute or subacute following a clinically apparent stroke, with symptoms that may stabilise or partially improve [7].
Gait impairment is characterised by a slow, shuffling gait, often with a wider base than that observed in idiopathic Parkinson’s disease (IPD) [5,6]. Postural instability is prominent, and postural reflexes are impaired early in the disease course. The lower limbs are typically more affected than the upper limbs, with spasticity rather than rigidity, brisk tendon reflexes, extensor plantar responses, and occasional clonus [5,6]. Upper limb involvement, when present, is usually milder and less asymmetric than in IPD, and resting tremor is uncommon [5].
As the disease progresses, patients frequently develop urinary urgency or incontinence and cognitive impairment, reflecting frontal–subcortical involvement [8]. Frontal release signs, including glabellar tap, snout, and palmomental reflexes, may be present [9]. Importantly, patients do not typically report diurnal fluctuation of symptoms [10]. Establishing the nature of symptom onset is essential, as after a decade of disease evolution, early diagnostic clues may be obscured.
Clinical subtypes
Rektor et al propose three clinical subtypes of the disease [1,11]. The acute or subacute post-stroke VP subtype is characterised by acute or subacute onset of parkinsonism that is usually asymmetric and responsive to dopaminergic drugs [2]. The more common insidious onset VP subtype presents with progressive parkinsonism with prominent postural instability, gait impairment, corticospinal, cerebellar, pseudobulbar, cognitive and urinary symptoms and poor responsiveness to dopaminergic drugs. This subtype often also presents with a higher-level gait disorder [3]. The third subtype is a mixed subtype which exhibits a combination of the aforementioned clinical features.
Although these subtypes are useful conceptually, overlap is common, and differentiation from idiopathic Parkinson’s disease can be challenging, particularly in older patients. Acute or subacute VP may mimic IPD due to asymmetry and partial dopaminergic responsiveness, whereas insidious-onset VP is more readily distinguished by early gait impairment, poor levodopa response, pyramidal signs, and cognitive or urinary features. Accurate classification therefore relies on integrating clinical phenotype, temporal evolution, and neuroimaging findings.
Vascular Parkinsonism versus Idiopathic Parkinson’s Disease
VP and IPD differ in terms of clinical characteristics, disease progression, prognosis and responses to treatment [12]. Consequently, it is crucial to differentiate between the two. Individuals with VP often present with difficulty walking, but show less flexion of the trunk, hips and knees, and better forward arm swing than patients with IPD [13]. Conversely patients with IPD typically present with asymmetric symptoms in the upper limbs initially. Cognitive impairment and urinary incontinence are more common in cases of VP, while resting tremor and olfactory dysfunction are more frequently observed in IPD (5,12, 14).
Differences between VP and IPD are also seen on brain imaging. In cases of VP, brain MRI will reveal infarction, haemorrhage, or signs of small vessel disease. In IPD, brain MRI can appear completely normal, however elderly patients may exhibit vascular changes as incidental findings, albeit these are significantly less prevalent than those observed in VP [15,16]. Furthermore, dopamine transporter scan (DaTSCAN) is usually normal in VP if the nigrostriatal pathway is not compromised, whereas in IPD it typically demonstrates asymmetrically reduced uptake (Figure 1).

Other neurodegenerative conditions should also be considered in the differential diagnosis, particularly atypical parkinsonian syndromes such as multiple system atrophy (MSA) and progressive supranuclear palsy. Prominent autonomic dysfunction, rapid progression, early falls, gaze palsy, or severe sleep disorders such as REM sleep behaviour disorder should prompt consideration of alternative diagnoses. Neuroimaging findings must always be interpreted in the clinical context, as patients with idiopathic Parkinson’s disease may also have incidental cerebrovascular disease or white matter changes unrelated to their parkinsonian syndrome.
Despite the differences between VP and IPD, many patients are probably misdiagnosed. In a post-mortem study of 28 patients with VP, only 6 had been correctly diagnosed, while an autopsy study of 39 patients with parkinsonism found that 5 had vascular aetiology that had gone unrecognised antemortem [17]. Other studies have suggested that VP may represent one of the most common differential diagnoses for IPD [18,19].
Diagnosis
Currently, there are no universally accepted guidelines for the diagnosis of VP, indicating a need for further research, evaluation and analysis.
Based on clinical findings and pathology, Zijlmans et al. have proposed the following criteria:
a) Parkinsonism
b) Cerebrovascular disease visible on MRI or CT or signs/symptoms consistent with stroke disease
c) A relation between a) and b), either in the form of acute hemiparkinsonism resulting from infarction or haemorrhage in the nigrostriatal pathway (type 1), or small vessel disease in the white matter with gradual development of parkinsonism (type 2) [20].
When to suspect vascular parkinsonism
Clinicians should suspect vascular parkinsonism in patients presenting with early and prominent gait disturbance, particularly when symptoms are symmetrical, lower-limb predominant, and poorly responsive to levodopa. Additional red flags include early postural instability, pyramidal signs, urinary incontinence, cognitive impairment, and absence of resting tremor.
A detailed cardiovascular history is essential and should include assessment of hypertension, diabetes mellitus, hyperlipidaemia, smoking status, atrial fibrillation, prior stroke or transient ischaemic attack. In the presence of these features, magnetic resonance imaging of the brain should be requested to assess for strategic infarction or cerebral small vessel disease.
In general, magnetic resonance imaging (MRI) of the brain is necessary to determine whether there is damage to the nigrostriatal pathway (Figure 2) or small vessel disease in the white matter (Figure 3). Conversely, computed tomography (CT) scans of the brain are not as effective for diagnosis, primarily due to their reduced sensitivity in detecting lacunar infarcts and small vessel disease [11].


Management
Dopaminergic medications demonstrate reduced efficacy in VP compared to IPD. The most extensively researched treatment for VP is levodopa, with a meta-analysis indicating that 30% of patients have a favourable response [21]. Holm H et al suggest that individuals with subtype 1 benefit the most, likely due to the presence of vascular lesions in the nigrostriatal pathway, resulting in dopamine deficiency [22]. In contrast, patients with small vessel disease in the white matter mainly have dysfunctional thalamocortical pathways with no changes in dopamine levels [22].
| Sign up to the ACNR email newsletter here |
Disease progression and prognosis differ between vascular parkinsonism subtypes. Patients with a single strategic infarct involving the nigrostriatal pathway may show relative clinical stability or partial responsiveness to dopaminergic therapy, whereas those with diffuse cerebral small vessel disease typically experience progressive gait impairment, cognitive decline, and increasing dependency. Secondary stroke prevention is therefore a cornerstone of management. Although no clinical trials have specifically evaluated vascular risk reduction in vascular parkinsonism, aggressive management of hypertension, diabetes mellitus, dyslipidaemia, and atrial fibrillation, together with antiplatelet therapy and statin use in accordance with established stroke prevention guidelines, is biologically plausible and may help slow progression of white matter disease [21,23].
Unfortunately, there are no other pharmacological treatments available for either subtype.
Consequently, individuals diagnosed with VP should be informed about the potential for further deterioration in mobility and cognitive function which may present an opportunity to discuss advanced directives early in the disease trajectory.
Interdisciplinary rehabilitation programmes for VP aim to enhance quality of life through symptom management, promoting independence and minimising disability. These programmes focus on improving mobility, gait, balance, and functional independence [24,25]. They also incorporate strategies for fall prevention, aerobic and strength training and may include cognitive rehabilitation, psychological support, exercises for dysarthria and management techniques for dysphagia, such as dietary modification and swallowing manoeuvres [25]. As the condition progresses environmental adaptations and assistive devices may be required. Although evidence supporting effectiveness of rehabilitation interventions in VP is limited there is considerable evidence of their effectiveness in IPD [25-27]. Consequently, all individuals experiencing VP related impairments should be referred to a specialist neurorehabilitation interdisciplinary team.
Conclusion
VP can arise from ischaemic or haemorrhagic strokes but is most frequently a consequence of brain white matter lesions and basal ganglia lacunes. The current literature and our clinical observations indicate that VP may be underrecognised.
VP should be suspected in individuals exhibiting characteristic clinical symptoms, relevant imaging findings and a lack of treatment response to levodopa. The clinical picture is dominated by symmetrical symptoms and difficulty walking early in the disease course, as well as cognitive impairment and difficulties with urination. Typically, the DaT scan is normal. Patients with VP often experience more rapid functional decline and may have reduced survival compared with idiopathic Parkinson’s disease, largely due to comorbid cerebrovascular disease.
Proactive management of vascular risk factors early in the disease course is likely to slow disease progression, underscoring the importance of an accurate and timely diagnosis.
References
- Postuma RB, Berg D, Stern M et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015; 30: 1591-601. https://doi.org/10.1002/mds.26424
- Critchley M. Arteriosclerotic parkinsonism. Brain 1929; 52: 23-83. https://doi.org/10.1093/brain/52.1.23
- Gupta D, Kuruvilla A. Vascular parkinsonism: what makes it different? Postgrad Med J 2011; 87: 829-36. https://doi.org/10.1136/postgradmedj-2011-130051
- Shrimanker I, Tadi P, Sánchez-Manso JC. Parkinsonism [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542224/
- Kalra S, Differentiating vascular parkinsonism from idiopathic Parkisonon’s disease: a systematic review. Mov Disord; 2010; 25: 149-56 https://doi.org/10.1002/mds.22937
- Newman EJ et al. Accuracy of Parkison’s disease diagnosis in 610 general practice patients in West of Scotland. Mov. Disord. 2009; 24:2379-85 https://doi.org/10.1002/mds.22829
- Tolosa, E. S and Santamaria, J. Parkisonism and basal ganglia infarcts. Neurology 34, 1516-1518 (1984). https://doi.org/10.1212/WNL.34.11.1516
- Rektor, I et al. Vasular pathology in patients with idiopathic Parkinson’s disease. Parkisonism Relat. Disord. 15, 24-29 (2009). https://doi.org/10.1016/j.parkreldis.2008.02.007
- Okuda, B. et al Primitive reflexes distinguish vascular parkinsonism from Parkison’s disease. Clin. Neurol. Neurosurg. 110, 562-565 (2008) https://doi.org/10.1016/j.clineuro.2008.02.013
- Folthyne, T. et al. Vascular parkinsonism: a review of the precision and frequency of the diagnosis. Neuroepidemiology 21, 1-7 (2002) https://doi.org/10.1159/000048607
- Rektor I et al An updated diagnostic approach to subtype definition of vascular parkinsonism – Recommendations from an expert working group. Review. Parkinsonism Relat Disord. 2018 Apr:49:9-16 https://doi.org/10.1016/j.parkreldis.2017.12.030
- Kalra S, Grosset DG, Benamer HT. Differentiating vascular parkinsonism from idiopathic Parkinson’s disease: a systematic review. Mov Disord 2010; 25: 149-56. https://doi.org/10.1002/mds.22937
- Zijlmans JC et al. Quantitative gait analysis in patients with vascular parkinsonism. Mov Disord 1996; 11: 501-8. https://doi.org/10.1002/mds.870110505
- Yamanouchi H, Nagura H. Neurological signs and frontal white matter lesions in vascular parkinsonism. A clinicopathologic study. Stroke 1997; 28: 965-9. https://doi.org/10.1161/01.STR.28.5.965
- Demirkiran M, Bozdemir H, Sarica Y. Vascular parkinsonism: a distinct, heterogeneous clinical entity. Acta Neurol Scand 2001; 104: 63-7. https://doi.org/10.1034/j.1600-0404.2001.104002063.x
- Dunet V, Deverdun J, Charroud C et al. MRI volumetric morphometry in vascular parkinsonism. J Neurol 2017; 264: 1511-9. https://doi.org/10.1007/s00415-017-8561-5
- Glass PG et al, The clinical features of pathologically confirmed vascular parkinsonism. J neurol. Neurosurg Psychiatry 2012; 83: 1027-9 https://doi.org/10.1136/jnnp-2012-302828
- Caslake R et al. Changes in diagnosis with follow-up in an incident cohort of patients with parkinsonism. J Neurol Neurosurg Psychiatry 2008; 79: 1202-7. https://doi.org/10.1136/jnnp.2008.144501
- Newman EJ et al. Accuracy of Parkinson’s disease diagnosis in 610 general practice patients in the West of Scotland. Mov Disord 2009; 24: 2379-85. https://doi.org/10.1002/mds.22829
- Zijlmans JC et al. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord 2004; 19: 630-40. https://doi.org/10.1002/mds.20083
- Miguel-Puga A, Villafuerte G, Salas-Pacheco J et al. Therapeutic Interventions for Vascular Parkinsonism: A Systematic Review and Meta-analysis. Front Neurol 2017; 8: 481. https://doi.org/10.3389/fneur.2017.00481
- Holm H et al, Vascular Parkisonism, Tidsskr Nor Laegeforen, 2023 May 4;143(7).
- Dufouil C, Chalmers J, Coskun O et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005; 112: 1644-50. https://doi.org/10.1161/CIRCULATIONAHA.104.501163
- Hohler AD at al. Effectiveness of an inpatient movement disorders program for patients with atypical parkinsonism. Parkinson’s Disease. 2012;2012(1):871974. https://doi.org/10.1155/2012/871974
- Saluja A, Goyal V, Dhamija RK. Multi-modal rehabilitation therapy in Parkinson’s disease and related disorders. Annals of Indian Academy of Neurology. 2023 Jan 1;26(Suppl 1):S15-25. https://doi.org/10.4103/aian.aian_164_22
- Leung IH, Walton CC, Hallock H, Lewis SJ, Valenzuela M, Lampit A. Cognitive training in Parkinson disease: a systematic review and meta-analysis. Neurology. 2015 Nov 24;85(21):1843-51. https://doi.org/10.1212/WNL.0000000000002145
- Amara AW, Memon AA. Effects of exercise on non-motor symptoms in Parkinson’s disease. Clinical therapeutics. 2018 Jan 1;40(1):8-15. https://doi.org/10.1016/j.clinthera.2017.11.004

